Substance / Medication

Thyroxine

Overview

Active Ingredient
levothyroxine
RxNorm CUI
10582

Indications

® NP Thyroidtablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of th

Labeler: Acella Pharmaceuticals, LLCUpdated: 2026-01-27T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threaten

Contraindications

When this intervention should not be used

Thyroid hormone preparations are generally contraindicated in patients with diagnosed but as yet uncorrected adrenal cortical insufficiency, untreated thyrotoxicosis, and apparent hypersensitivity to any of their active or extraneous constituents. There is no well-documented evidence from the litera

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

3 trials linked to this intervention

3
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Effectiveness of low dose thyroxine in patients with subclinical hypothyroidism and migraine; systematic review and meta-analysis.
Alokley Alia, ALNasser Maryam N, Alabdulqader Razan Anwar et al. · BMC Neurol · 2025
PMID: 40329276Meta-AnalysisFull text (PMC)
Thyroxine changes in COVID-19 pandemic: A systematic review and meta-analysis.
Li Ziqi, Hou Pengwei, Mu Shuwen et al. · Front Endocrinol (Lausanne) · 2023
PMID: 36860369Meta-AnalysisFull text (PMC)
The effect of metformin therapy on serum thyrotropin and free thyroxine concentrations in patients with type 2 diabetes: a meta-analysis.
Amirabadizadeh Alireza, Amouzegar Atieh, Mehran Ladan et al. · Sci Rep · 2023
PMID: 37907510Meta-AnalysisFull text (PMC)
Free triiodothyronine and free thyroxine hormone levels in relation to breast cancer risk: a meta-analysis.
Lei Zhengwu, Zeng Bin, Wu Lina et al. · Endokrynol Pol · 2022
PMID: 35381094Meta-Analysis
Influence of thyroxine supplementation on orthodontically induced tooth movement and/or inflammatory root resorption: A systematic review.
Berry Stefani, Javed Fawad, Rossouw Paul Emile et al. · Orthod Craniofac Res · 2021
PMID: 32991769Meta-Analysis
The Association Between COVID-19 and Thyroxine Levels: A Meta-Analysis.
Chen Yiru, Li Xiuneng, Dai Yu et al. · Front Endocrinol (Lausanne) · 2021
PMID: 35058879Meta-AnalysisFull text (PMC)
Effect of l-thyroxine administration before breakfast vs at bedtime on hypothyroidism: A meta-analysis.
Pang Xiao, Pu Tao, Xu Li et al. · Clin Endocrinol (Oxf) · 2020
PMID: 32022947Meta-Analysis
Effect of Addition of Thyroxine in the Treatment of Graves' Disease: A Systematic Review.
Li Jun, Bai Litao, Wei Fan et al. · Front Endocrinol (Lausanne) · 2020
PMID: 33569041Meta-AnalysisFull text (PMC)
Thyroxine replacement for subfertile women with euthyroid autoimmune thyroid disease or subclinical hypothyroidism.
Akhtar M Ahsan, Agrawal Rina, Brown Julie et al. · Cochrane Database Syst Rev · 2019
PMID: 31236916Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Thyroxine (substance)
SNOMED CT
73187006
UMLS CUI
C0040165
RxNorm CUI
10582
Labeler
Acella Pharmaceuticals, LLC

Clinical Data

This intervention maps to 7 entities in the Ltrl knowledge graph.

6
Conditions
1
Biomarkers
0
Specialists
0
Symptoms
3
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.